TABLE 1.

SBA-MenC, PSC, and PRP immune responses 1 month after primary vaccination

GroupTime pointaSBA-MenCPSCPRP
% (95% CI*)b of subjects with titer of ≥1:8GMTc (95% CI)% (95% CI*) of subjects with concn of ≥0.30 μg/mlGMC (μg/ml) (95% CI)% (95% CI*) of subjects with concn of ≥0.15 μg/mlGMC (μg/ml) (95% CI)
MenC (n = 90)PD295.5 (88.9, 98.8)651.8* (475.2, 894.1)100.0 (96.0, 100.0)33.86 (28.19, 40.65)94.4 (87.4, 98.2)2.04 (1.40, 2.98)
PD3100.0 (95.9, 100.0)1,008.2* (802.0, 1,267.3)100.0 (96.0, 100.0)30.13 (25.54, 35.55)100.0 (95.9, 100.0)4.06* (3.06, 5.39)
MenCads (n = 99)PD299.0 (94.4, 100.0)390.2* (308.9, 493.1)100.0 (96.3, 100.0)25.23 (21.87, 29.11)95.9 (89.8, 98.9)2.04 (1.46, 2.84)
PD398.0 (92.9, 99.8)389.7* (307.2, 494.2)100.0 (96.3, 100.0)20.59* (18.18, 23.31)99.0 (94.4, 100.0)4.03* (3.11, 5.23)
Hib10-MenC10 (n = 94)PD296.8 (91.0, 99.3)584.7* (447.7, 763.5)100.0 (96.1, 100.0)28.04 (24.09, 32.65)96.8* (90.9, 99.3)2.66* (1.85, 3.80)
PD398.9 (94.2, 100.0)732.2* (586.2, 914.6)100.0 (96.0, 100.0)24.20* (20.99, 27.91)100.0 (96.0, 100.0)12.09* (9.63, 15.17)
Hib5-MenC5 (n = 95)PD2100.0 (96.1, 100.0)679.6* (562.8, 820.6)100.0 (96.1, 100.0)26.68 (23.00, 30.95)96.8* (90.9, 99.3)3.40* (2.38, 4.85)
PD3100.0 (96.2, 100.0)944.2* (779.4, 1,143.8)100.0 (96.2, 100.0)21.48* (18.82, 24.52)100.0 (96.2, 100.0)14.03* (11.33, 17.38)
Control (n = 105)PD298.1 (93.2, 99.8)1,059.0 (822.6, 1,363.4)100.0 (96.5, 100.0)31.06 (26.69, 36.14)88.5 (80.7, 93.9)1.27 (0.89, 1.82)
PD3100.0 (96.5, 100.0)1,400.7 (1,165.4, 1,683.5)100.0 (96.5, 100.0)34.31 (30.10, 39.12)97.1 (91.9, 99.4)2.78 (2.11, 3.65)
  • a PD2, 1 month after dose 2; PD3, 1 month after dose 3.

  • b 95% CI*, exact 95% CI.

  • c Asterisks indicate statistically significant differences relative to the control group.